Income tax demand of about Rs 11.88 cr for AY 2022-23, company to appeal at ITAT
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts more than Nifty Microcap 250 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
AstraZeneca Pharma India received a final income tax assessment order for assessment year 2022-23, with adjustments proposed on legacy transfer pricing and corporate tax issues. The demand is about Rs 11.88 crores, excluding interest and penalty. The company plans to challenge the order at the Income Tax Appellate Tribunal (ITAT). This follows a draft order disclosed in March 2025.
Rs 11.88 cr tax demand may pressure short-term finances, but the planned appeal at ITAT could reduce or reverse it.